Get started
Amphastar Pharmaceuticals, Inc.Amphastar Pharmaceuticals, Inc.Amphastar Pharmaceuticals, Inc.

Amphastar Pharmaceuticals, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals Bonds

AMPH chart


Full chart

AMPH upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪2.24 B‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
17.77
Basic EPS (TTM)
3.26 USD
Net income (FY)
‪137.54 M‬ USD
Revenue (FY)
‪644.39 M‬ USD
Shares float
‪36.12 M‬
Beta (1Y)
0.75

Employees


Employees (FY)
‪1.76 K‬
Change (1Y)
+146 +9.04%
Revenue / Employee (1Y)
‪365.93 K‬ USD
Net income / Employee (1Y)
‪78.11 K‬ USD

About Amphastar Pharmaceuticals, Inc.


Sector
Health Technology
CEO
Yong Feng Zhang
Headquarters
Rancho Cucamonga
Website
amphastar.com
Founded
1996
FIGI
BBG000BW90S6
Amphastar Pharmaceuticals, Inc. engages in developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, and insulin active pharmaceutical ingredient. It operates through Finished Pharmaceutical Products and Active Pharmaceutical Ingredients Products segments. The Finished Pharmaceutical Products segment manufactures, markets, and distributes Primatene Mist, enoxaparin, naloxone, phytonadione, lidocaine, and other critical and non-critical care drugs. The Active Pharmaceutical Ingredients Products segment offers RHI API and porcine insulin API for external customers and internal product development. The company was founded by Zi-Ping Luo and Yong Feng Zhang on February 29, 1996 and is headquartered in Rancho Cucamonga, CA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

AMPH news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

AMPH highest yielding bonds


AMPH5896384
Amphastar Pharmaceuticals, Inc. 2.0% 15-MAR-2029
Yield to maturity
1.09%
Maturity date
Mar 15, 2029

Explore more bonds 

Frequently Asked Questions


The current price of AMPH is 48.49 USD — it has decreased by −13.69% in the past 24 hours. Watch Amphastar Pharmaceuticals, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Amphastar Pharmaceuticals, Inc. stocks are traded under the ticker AMPH.
AMPH stock has fallen by −8.53% compared to the previous week, the month change is a −1.87% fall, over the last year Amphastar Pharmaceuticals, Inc. has showed a 1.00% increase.
We've gathered analysts' opinions on Amphastar Pharmaceuticals, Inc. future price: according to them, AMPH price has a max estimate of 66.00 USD and a min estimate of 55.00 USD. Watch AMPH chart and read a more detailed Amphastar Pharmaceuticals, Inc. stock forecast: see what analysts think of Amphastar Pharmaceuticals, Inc. and suggest that you do with its stocks.
AMPH reached its all-time high on Aug 9, 2023 with the price of 67.66 USD, and its all-time low was 6.67 USD and was reached on Jun 25, 2014. View more price dynamics on AMPH chart.
See other stocks reaching their highest and lowest prices.
AMPH stock is 5.53% volatile and has beta coefficient of 0.75. Track Amphastar Pharmaceuticals, Inc. stock price on the chart and check out the list of the most volatile stocks — is Amphastar Pharmaceuticals, Inc. there?
Today Amphastar Pharmaceuticals, Inc. has the market capitalization of ‪2.24 B‬, it has increased by 2.32% over the last week.
Yes, you can track Amphastar Pharmaceuticals, Inc. financials in yearly and quarterly reports right on TradingView.
Amphastar Pharmaceuticals, Inc. is going to release the next earnings report on Mar 12, 2025. Keep track of upcoming events with our Earnings Calendar.
AMPH earnings for the last quarter are 0.96 USD per share, whereas the estimation was 0.99 USD resulting in a −2.83% surprise. The estimated earnings for the next quarter are 0.98 USD per share. See more details about Amphastar Pharmaceuticals, Inc. earnings.
Amphastar Pharmaceuticals, Inc. revenue for the last quarter amounts to ‪191.21 M‬ USD, despite the estimated figure of ‪194.67 M‬ USD. In the next quarter, revenue is expected to reach ‪194.11 M‬ USD.
AMPH net income for the last quarter is ‪40.43 M‬ USD, while the quarter before that showed ‪37.95 M‬ USD of net income which accounts for 6.54% change. Track more Amphastar Pharmaceuticals, Inc. financial stats to get the full picture.
No, AMPH doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 8, 2024, the company has ‪1.76 K‬ employees. See our rating of the largest employees — is Amphastar Pharmaceuticals, Inc. on this list?
Like other stocks, AMPH shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Amphastar Pharmaceuticals, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Amphastar Pharmaceuticals, Inc. technincal analysis shows the neutral today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Amphastar Pharmaceuticals, Inc. stock shows the buy signal. See more of Amphastar Pharmaceuticals, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.